Recent Underperformance Puts Cooper Companies Under Closer Scrutiny

Cooper Companies (COO) has drawn investor attention after its shares fell 9.5% over the past six months while the S&P 500 gained 12.9%, raising questions about sentiment toward the stock.

At a share price of US$76.73, Cooper Companies has seen a 30 day share price return of 7.18% and a 90 day share price return of 22.08%. The 1 year total shareholder return of 4.39% contrasts with weaker 3 and 5 year total shareholder returns, which signals that momentum has picked up recently after a tougher multi year stretch.

If Cooper Companies’ recent moves have you reassessing opportunities in healthcare, this is a good moment to broaden your search through 42 healthcare AI stocks

Bulls see Cooper Companies as a discounted compounder after the recent rebound. Bears point to slower expected revenue growth and past capital efficiency concerns. Which side does the current valuation support next?

Most Popular Narrative: 4.8% Undervalued

Cooper Companies’ most followed narrative pegs fair value at $80.57, slightly above the last close at $76.73, which leaves a modest implied discount.

The company recently resolved its manufacturing constraints for MyDAY, its premium daily silicone hydrogel contact lens, and is now accelerating global rollout with expanded fitting sets, trial lenses, and over 30 new private label contracts. This is expected to drive substantial revenue growth and market share gains as pent up demand is fulfilled and the premium offering captures higher margins over time.

Want to see why this narrative still supports a higher price than today? It rests on faster earnings growth, wider margins, and a future valuation multiple that has to compress meaningfully. The full story sits in how those moving parts line up across the next few years.

Result: Fair Value of $80.57 (UNDERVALUED)

However, Cooper Companies still faces pressure from softer fertility and IUD markets, as well as slower contact lens market growth, which could challenge the upbeat earnings narrative.

Another View: Cooper Companies Looks Expensive On Earnings

The SWS DCF model points to upside for Cooper Companies, yet the current P/E of 63.5x tells a different story. It is well above the Medical Equipment industry average of 27.2x, the peer average of 25x, and the 36.2x fair ratio that the market could move towards. If sentiment cools, that gap can close through price rather than earnings, so which signal do you trust more right now?

For a closer look at how much weight to place on today's earnings multiple versus cash flow estimates, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of caution and optimism around Cooper Companies creates a real fork in the road. Review the data now and decide where you stand with the 2 key rewards and 1 important warning sign

Looking For More Ideas Beyond Cooper Companies?

If you are weighing your next move after reviewing Cooper Companies, do not stop here. The right watchlist can be built before prices move.

• Target potential mispricing by checking companies that appear cheaper than their fundamentals suggest through the 52 high quality undervalued stocks
• Secure more predictable income ideas by scanning higher yielding payers using the 12 dividend fortresses
• Prioritize resilience by reviewing companies screened in the 78 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.